ADOCIA

French researchers developed a hydrogel system reducing diabetes medication dosing to once a month, using a gel that slowly releases semaglutide, effective for type 2 diabetes and weight loss.

A slow-release semaglutide hydrogel could enable once-monthly injections of Wegovy or Ozempic, replacing weekly shots, according to a study presented at the European Association for the Study of Diabetes’ annual meeting. The gel, developed by ADOCIA, releases semaglutide steadily and could simplify treatment for diabetes and obesity, improving adherence and quality of life.

French scientists unveiled a novel hydrogel version of semaglutide, allowing monthly injections instead of weekly. Developed by Adocia, it aims to improve adherence rates for diabetes and weight loss drugs. Lab tests and rats showed slow, steady release without inflammation. Plans include pig testing and potential human trials.

French researchers developed a hydrogel for once-a-month semaglutide injections, aiming to improve adherence in type 2 diabetes and weight control. The hydrogel, tested in rats, showed sustained release over a month with no adverse reactions, and future tests in pigs are planned before clinical trials.

French researchers developed a hydrogel delivery system for semaglutide, potentially reducing dosing to once a month, easing adherence for type 2 diabetes and obesity patients. The hydrogel, tested in vitro and on rats, showed sustained release over 1-3 months with no adverse reactions, paving the way for future pig trials and potential clinical trials.